Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

JF, Robertson; A, Llombart-Cussac; J, Rolski; D, Feltl; J, Dewar; E, Macpherson; J, Lindemann; MJ, Ellis

doi:10.1200/jco.2008.21.1136

Public

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

Shared by NobleBlocks on Aug 24, 2009 • 12:00 AM UTC

Authors:

Robertson JF

Llombart-Cussac A

Rolski J

Abstract

Purpose To compare the clinical activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-positive breast cancer in postmenopausal women.Patients and methods FIRST (Fulv...

Discussions